Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical Hainan Co Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Qilu Pharmaceutical (Hainan) Co., Ltd. (China)
  • Plaintiff’s Counsel: Saul Ewing LLP; Quinn Emanuel Urquhart & Sullivan, LLP
• Case Identification: 2:26-cv-01633, D.N.J., 02/18/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendant's business of developing, marketing, and selling generic pharmaceutical products throughout the United States, including in the district. The complaint also alleges the district is a likely destination for the accused generic product and that Defendant has previously consented to personal jurisdiction in this district.
• Core Dispute: Plaintiff alleges that Defendant’s submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff’s LIVTENCITY® (maribavir) drug product constitutes an act of infringement of six U.S. patents.
• Technical Context: The dispute is in the field of antiviral pharmaceuticals, specifically concerning maribavir, a kinase inhibitor used for treating cytomegalovirus (CMV) infections in post-transplant patients.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of ANDA No. 221142 with a Paragraph IV Certification, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by its proposed generic product. Plaintiff was notified of the ANDA filing via a letter from Defendant dated January 9, 2026.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632 - “Maribavir Isomers, Compositions, Methods of Making and Methods of Using”

The Invention Explained

• Problem Addressed: The patent describes the unexpected discovery that the antiviral drug maribavir can isomerize in vivo (i.e., inside the body) into different molecular forms, which may have lower biological activity (Compl., Ex. A, ’632 Patent, col. 2:5-15). This isomerization is believed to dilute the drug’s effective concentration, potentially explaining the failure of a prior Phase 3 clinical study that, unlike an earlier successful study, allowed patients to take the drug with food, a condition that may promote such isomerization (Compl., Ex. A, ’632 Patent, col. 2:16-56).
• The Patented Solution: The invention provides methods to counteract or mitigate the effects of this in vivo isomerization to enhance the drug's efficacy (Compl., Ex. A, ’632 Patent, abstract). The proposed solutions include specific treatment protocols, such as administering the drug under fasted conditions, adjusting the dosage, and using specific formulations designed to limit isomerization (Compl., Ex. A, ’632 Patent, col. 3:50-col. 4:1). The invention also covers the isomers themselves and methods for monitoring their levels in patients (Compl., Ex. A, ’632 Patent, col. 4:2-29).
• Technical Importance: The technology provides a potential solution to overcome a previously unrecognized chemical instability that may have caused a clinical trial failure, offering a way to improve the therapeutic effectiveness of maribavir.

Key Claims at a Glance

• The complaint asserts infringement of one or more claims without specifying them Compl. ¶33 Independent claim 1 is representative of the patent’s method-of-use claims.
• Independent Claim 1: A method for treating a herpes viral infection, with the following essential elements:
  • Orally administering the compound 5,6-dichloro-2-(isopropylamino)-1-(B-L-ribofuranosyl)-1H-benzimidazole, or an isomer thereof
  • In an amount of 400 mg twice a day
  • To a patient who is a stem cell transplant recipient
• The complaint does not explicitly reserve the right to assert dependent claims, but this is standard practice.

U.S. Patent No. 12,213,989 - “Use of Maribavir in Treatment Regimens”

The Invention Explained

• Problem Addressed: The patent addresses the challenge of administering maribavir to transplant patients, who often receive numerous other medications to manage comorbidities (Compl., Ex. B, ’989 Patent, col. 1:21-25). Specifically, it recognizes that certain co-administered drugs, such as CYP3A4 inducers (e.g., some anticonvulsants), can decrease a patient's exposure to maribavir, potentially reducing its antiviral effect (Compl., Ex. B, ’989 Patent, col. 5:9-14).
• The Patented Solution: The patent discloses specific treatment regimens to manage these drug-drug interactions. The core solution involves increasing the dosage of maribavir when it is co-administered with a CYP3A4 inducer to counteract the reduced exposure and maintain therapeutic effectiveness (Compl., Ex. B, ’989 Patent, col. 2:1-14). The patent provides specific increased dosage amounts for use with particular co-administered drugs (Compl., Ex. B, ’989 Patent, col. 47:9-17).
• Technical Importance: The invention provides specific, clinically relevant dosing instructions that allow for the safe and effective use of maribavir in a complex patient population that is concurrently taking other essential medications known to cause drug interactions.

Key Claims at a Glance

• The complaint asserts infringement of one or more claims without specifying them Compl. ¶42 Independent claim 1 is representative.
• Independent Claim 1: A method of treating a CMV infection, with the following essential elements:
  • Administering maribavir in an amount of 1200 mg orally twice-daily
  • To a patient who is a transplant recipient
  • Who is concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital
• The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 12,295,940 - “Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto”

• Technology Synopsis: This patent is directed to improved methods for synthesizing maribavir that result in a higher overall yield and provide better control over impurities (Compl., Ex. C, ’940 Patent, col. 1:15-19; Compl., Ex. C, ’940 Patent, col. 8:62-col. 9:11). The invention also covers compositions of maribavir characterized by very low levels of specific process-related impurities (Compl., Ex. C, ’940 Patent, abstract).
• Asserted Claims: One or more claims are asserted Compl. ¶51 Representative independent claim 1 is a composition claim comprising maribavir and specific related compounds (impurities) (Compl., Ex. C, ’940 Patent, col. 143:42-53).
• Accused Features: The Defendant's ANDA product is alleged to be a composition that will infringe one or more claims of the ’940 Patent Compl. ¶53

U.S. Patent No. 12,433,907 - “Use of Maribavir in Treatment Regimens”

• Technology Synopsis: This patent, related to the ’989 Patent, addresses drug-drug interactions between maribavir and other drugs commonly taken by transplant patients, such as CYP3A4 inducers (Compl., Ex. D, ’907 Patent, col. 1:23-29). It provides specific dosage adjustments for maribavir to maintain its efficacy when co-administered with such interacting drugs (Compl., Ex. D, ’907 Patent, col. 2:1-24).
• Asserted Claims: One or more claims are asserted Compl. ¶60 Representative independent claim 1 is a method claim for treating CMV by administering 1200 mg of maribavir twice daily to a transplant patient also receiving phenytoin or phenobarbital (Compl., Ex. D, ’907 Patent, col. 45:15-23).
• Accused Features: The complaint alleges that the proposed labeling for the Defendant's ANDA product will induce infringement of the claimed methods Compl. ¶63

U.S. Patent No. 12,447,169 - “Maribavir Isomers, Compositions, Methods of Making and Methods of Using”

• Technology Synopsis: This patent, related to the ’632 Patent, addresses the problem of in vivo isomerization of maribavir and its impact on therapeutic efficacy (Compl., Ex. E, ’169 Patent, col. 2:5-15). The invention provides methods for using maribavir, such as administration in a fasted state, to mitigate this isomerization and improve the drug's bioavailability and effectiveness (Compl., Ex. E, ’169 Patent, abstract; Compl., Ex. E, ’169 Patent, col. 4:1-14).
• Asserted Claims: One or more claims are asserted Compl. ¶69 Representative independent claim 1 is a method claim for treating CMV by orally administering 400 mg of the compound twice a day (Compl., Ex. E, ’169 Patent, col. 7:14-20).
• Accused Features: The complaint alleges that the proposed labeling for the Defendant's ANDA product will induce infringement of the claimed methods Compl. ¶72

U.S. Patent No. 12,447,170 - “Use of Maribavir in Treatment Regimens”

• Technology Synopsis: This patent, related to the ’989 and ’907 Patents, is directed to managing drug-drug interactions when administering maribavir to transplant recipients (Compl., Ex. F, ’170 Patent, col. 1:23-29). It discloses specific methods for adjusting maribavir dosage upward when co-administered with drugs that are CYP3A4 inducers to ensure therapeutic levels of maribavir are maintained (Compl., Ex. F, ’170 Patent, col. 2:1-24).
• Asserted Claims: One or more claims are asserted Compl. ¶78 Representative independent claim 1 is a method claim for treating CMV by administering 1200 mg of maribavir twice-daily to a patient also receiving an anticonvulsant from an efficacy perspective (Compl., Ex. F, ’170 Patent, col. 45:9-20).
• Accused Features: The complaint alleges that the proposed labeling for the Defendant's ANDA product will induce infringement of the claimed methods Compl. ¶81

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Defendant Qilu’s proposed generic version of LIVTENCITY®, identified as “maribavir tablets, 200 mg” in ANDA No. 221142 (“Qilu’s ANDA Product”) Compl. ¶27 Compl. ¶31

Functionality and Market Context

• Qilu’s ANDA Product is a pharmaceutical tablet containing 200 mg of the active ingredient maribavir Compl. ¶27 It is intended for oral administration for the treatment of post-transplant cytomegalovirus (CMV) infection/disease in certain adult and pediatric patients Compl. ¶10 The complaint alleges that the product is intended to be a generic version of Plaintiff’s LIVTENCITY® drug product and, upon FDA approval, will be manufactured, used, and sold in the United States Compl. ¶¶28, 31

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

’632 Patent Infringement Allegations

’989 Patent Infringement Allegations

Identified Points of Contention

• Scope Questions: A primary issue for the asserted method claims will be the content of the Defendant's proposed product label. The analysis will question whether the label encourages, recommends, or promotes an infringing use. For the ’989 Patent, this raises the question of whether the label will specifically instruct a 1200 mg twice-daily dose of maribavir when co-administered with phenytoin or phenobarbital, or if it merely provides this as one of several options.
• Technical Questions: For the composition claims of the ’940 Patent, the dispute may center on analytical chemistry. The analysis will raise the question of whether Qilu’s ANDA product, as manufactured, actually contains the specific impurities at the levels recited in the claims.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of specific claim terms that may be in dispute. However, based on the subject matter of the patents, the following terms may become central to the case.

The Term: "fasted condition" (relevant to the ’632 and ’169 Patents)

• Context and Importance: The technical premise of the ’632 and ’169 Patents is that administering maribavir in a "fasted condition" mitigates in vivo isomerization and improves efficacy. The definition of this term is critical because infringement of method claims requiring this step will depend on whether the Defendant's product label instructs administration in a way that falls within the construed scope of the term.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: Practitioners may cite the general definition provided in the specification, which states the term means "the condition of not having consumed food during the period between from at least about 3 to 12 hours prior to the administration... to at least about 1 to 3 hours after" (Compl., Ex. E, ’169 Patent, col. 6:58-63).
  • Evidence for a Narrower Interpretation: Practitioners may point to the patent's background, which contrasts a "strict fasted dosing protocol" from a failed clinical trial with a protocol that allowed for administration with or without food (Compl., Ex. A, ’632 Patent, col. 2:45-56). This could support an argument that the term implies a more rigorous standard than a general instruction not to take with food.

The Term: "concomitantly exposed to or receiving" (from claim 1 of the ’989 Patent)

• Context and Importance: This term defines the required relationship between the administration of maribavir and the specified anticonvulsants. Its construction will determine whether infringement requires the drugs to be taken at the same time, on the same day, or simply during an overlapping period of treatment.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language itself clarifies the term by stating "wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant" (Compl., Ex. B, ’989 Patent, col. 47:15-17). This language provides strong support for a broad interpretation covering any overlapping therapeutic timeframe.
  • Evidence for a Narrower Interpretation: A defendant might argue that "concomitantly" implies a closer temporal link, but this argument appears weakened by the explicit clarifying language that follows in the claim itself.

VI. Other Allegations

Indirect Infringement

• The complaint alleges both induced and contributory infringement for all six patents-in-suit (e.g., Compl. ¶¶36-37; Compl. ¶¶45-46). The basis for inducement is the allegation that Defendant’s proposed product labeling will instruct and encourage physicians and patients to administer the generic drug in a manner that infringes the asserted method claims. The basis for contributory infringement is the allegation that the product is especially adapted for an infringing use and has no substantial non-infringing use (e.g., Compl. ¶37).

Willful Infringement

• The complaint does not explicitly allege "willful infringement." However, for each patent, it alleges the case is "an exceptional one" and requests attorneys' fees under 35 U.S.C. § 285 (e.g., Compl. ¶40). This allegation is based on the assertion that Defendant has had knowledge of the patents-in-suit since at least the date of its ANDA submission (e.g., Compl. ¶38).

VII. Analyst’s Conclusion: Key Questions for the Case

• A central issue will be one of induced infringement: For the multiple method-of-use patents asserted, will the court find that the Defendant's proposed product labeling instructs or encourages physicians to prescribe, and patients to use, the generic product in a manner that directly infringes the specific dosage and patient population requirements of the claims (e.g., the 1200 mg dose with concomitant anticonvulsants of the '989 patent family)?
• A key evidentiary question will be one of compositional identity: For the ’940 patent, which claims compositions of maribavir with specific impurity profiles, the case may depend on whether Plaintiff can demonstrate through analytical testing that the Defendant’s ANDA product, as formulated for regulatory approval, will necessarily fall within the scope of those composition claims.
• A foundational question will be the enforceability of dosage regimens: Can Plaintiff enforce patents on specific dosage adjustments (e.g., the '989 patent family) and administration conditions (e.g., the '632 patent family) that are derived from managing drug interactions and chemical properties, or will Defendant successfully argue these methods are invalid as obvious to a person of ordinary skill in the art of clinical pharmacology?